ConductScience.org, home

Paper33765447

The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis.

Bosman M and 8 others. Lancet Gastroenterol Hepatol, 2021. Cited by 68 papers, by iCite.

Cite this record

ConductScience Library. The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis. Papers, record 33765447. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33765447

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The placebo response rate in pharmacological trials in patients with irritable bowel syndrome: a systematic review and meta-analysis.
PubMed
Journal
Lancet Gastroenterol Hepatol
PubMed
Year
2021
PubMed
Publication types
Journal Article, Meta-Analysis, Systematic Review
PubMed
Citations, by iCite
68
iCite
Relative citation ratio, by iCite
5.63
iCite
Revised in PubMed
2021-06-24
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bosman MMichelle
2Elsenbruch SSigrid
3Corsetti MMaura
4Tack JJan
5Simrén MMagnus
6Winkens BBjorn
7Boumans TThimo
8Masclee AAd
9Keszthelyi DDaniel

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Abdominal PainMajor topic
Irritable Bowel SyndromeMajor topic
PlacebosMajor topic
Adult
Case-Control Studies
Europe
Female
Humans
Male
Placebo Effect
Randomized Controlled Trials as Topic
Severity of Illness Index
United States
United States Food and Drug Administration

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in33765446Optimising clinical trial design to manage placebo response in randomised controlled trials of irritable bowel syndrome.https://conductscience.org/library/papers/33765446

Source PubMed

Download CSV of comments and corrections

Cited by38

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 68 citations.

PMIDTitleJournalYearIn PapersSource
42922994
Investigating the contextual modulation of postoperative gastrointestinal motility: a methodological feasibility study combining a standardized intervention protocol with wireless motility capsule monitoring.
Front Psychol2026https://conductscience.org/library/papers/42922994PubMed
42823420Irritable bowel syndrome.Nat Rev Dis Primers2026https://conductscience.org/library/papers/42823420PubMed
42682476
Initiating multi-strain probiotics is associated with clinically meaningful symptom relief, better quality of life, and fewer treatment escalations in IBS-D/IBS-M: a Chinese real-world propensity-matched cohort study.
Front Med (Lausanne)2026https://conductscience.org/library/papers/42682476PubMed
42603224Biomarkers in Irritable Bowel Syndrome: Bridging Gut-Brain Mechanisms to Precision Care.Curr Gastroenterol Rep2026https://conductscience.org/library/papers/42603224PubMed
42558675Mapping research trends in irritable bowel syndrome and the gut microbiome: a cross-database bibliometric analysis.Front Microbiol2026https://conductscience.org/library/papers/42558675PubMed
42211410Efficacy and safety of modified Gwakjeongtang (herbal medicine) for diarrhea-predominant irritable bowel syndrome: A randomized, double-blind, placebo-controlled trial.Integr Med Res2026https://conductscience.org/library/papers/42211410PubMed
42100776Acupuncture for irritable bowel syndrome comorbid with anxiety and depression: study protocol for a placebo run-in, randomized clinical trial.Front Psychiatry2026https://conductscience.org/library/papers/42100776PubMed
42094852Internet-delivered cognitive behavioral therapy and FODMAP diet for adults with irritable bowel syndrome: A four-arm randomized controlled trial.Internet Interv2026https://conductscience.org/library/papers/42094852PubMed
42017290Bifidobacterium bifidum G9-1 Intake Improves Gastrointestinal Symptoms in Type 2 Diabetes Mellitus: An Open-Label, Randomized Controlled Trial (Binary STAR Study).Diabetes Obes Metab2026https://conductscience.org/library/papers/42017290PubMed
41922986Clinical and cost effectiveness of nurse led-structured management of diarrhoea predominant irritable bowel syndrome in primary care (Lincolnshire POACHER study); a randomised control trial.BMC Prim Care2026https://conductscience.org/library/papers/41922986PubMed
41827145Probiotics in Irritable Bowel Syndrome: An Umbrella Review of 27 Systematic Reviews on Methodological Quality and Certainty of Evidence.J Clin Med2026https://conductscience.org/library/papers/41827145PubMed
41353332
Chinese medicine (Tiao-Chang Ke-Min granules) placebo and nocebo effects for diarrhea-predominant irritable bowel syndrome: a study protocol for a randomized controlled trial based on a balanced experimental design.
BMC Complement Med Ther2025https://conductscience.org/library/papers/41353332PubMed
41327057Outcome measures for irritable bowel syndrome: a scoping review.BMC Med Res Methodol2025https://conductscience.org/library/papers/41327057PubMed
41177820Clinical Characteristics and Outcomes of Rome IV Diarrhea-Predominant Irritable Bowel Syndrome and Functional Diarrhea Prescribed With Ondansetron: A Real-World Study.Neurogastroenterol Motil2025https://conductscience.org/library/papers/41177820PubMed
41158898
Tenapanor for Irritable Bowel Syndrome With Constipation (IBS-C): A Systematic Review of Randomized Trials Assessing Food and Drug Administration (FDA) Composite Response, Durability, and Risk-of-Bias (RoB-2).
Cureus2025https://conductscience.org/library/papers/41158898PubMed
41114660Unraveling nocebo effects in visceral pain: negative suggestion and adverse treatment experience uniquely shape visceral pain unpleasantness.Pain2026https://conductscience.org/library/papers/41114660PubMed
40692549Randomised controlled trial: nutritional supplements to relieve irritable bowel syndrome symptoms by targeting the gut microbiota.J Nutr Sci2025https://conductscience.org/library/papers/40692549PubMed
40431448
Multistrain Probiotics Plus Vitamin D Improve Gut Barrier Function and Gut Microbiota Composition in Irritable Bowel Syndrome Without Constipation: Results from a Double-Blind, Randomized, Placebo-Controlled Trial.
Nutrients2025https://conductscience.org/library/papers/40431448PubMed
39867596Efficacy of vagus nerve stimulation in gastrointestinal disorders: a systematic review.Gastroenterol Rep (Oxf)2025https://conductscience.org/library/papers/39867596PubMed
39669195Herbal placebo response in clinical trials on irritable bowel syndrome: a systematic review and meta-analysis.Front Pharmacol2024https://conductscience.org/library/papers/39669195PubMed

See all 38 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33765447

GET https://conductscience.org/api/papers/v1/33765447/cited_by?page=2